Radiation solutions
for healthcare

CLERAD is a European leader in the detection of radiolabelled tissues. We develop and deliver cutting-edge technologies to support less invasive precision surgery.

Discover our solutions

Since 2000, CLERAD has designed and developed proprietary
medical devices
in its facilities in Clermont-Ferrand.

International distribution network

An established presence across four continents, supported by a purpose-structured and reliable distribution network.

French innovation

Devices designed, developed and manufactured in our Clermont‑Ferrand facilities by teams of expert physicians and biologists.

25 years of expertise

Recognized since 2000 as a leader in ionizing radiation detection and guided surgery.

Regulatory standards

Full, stringent compliance with ISO 13485 and CE and FDA markings to guarantee the very highest levels of patient safety.

Our complete range

We design and develop technologies that enable more precise and less invasive surgery.

CLERAD products

GAMMA-SUP II

The reference technology for the identification of deep lymph nodes with efficiency and ergonomics for minimal surgery.

PAPILLON +

The contact radiotherapy system to deliver the optimal dose in just a few minutes.

GAMMA-AM

High sensitivity monitoring probe dedicated to isolated limb perfusion.

GAMMA-NODE

Gamma Compact camera optimized for intraoperative identification assistance.

Distribution Products

French expertise driving oncology forward

Founded in 2000 by Philippe Brette (PhD Physics), CLERAD has established itself as a leader in the ionizing radiation detection solutions.

Our organization based in Clermont-Ferrand integrates the entire value chain: from research conducted by our physicists and biologists through to manufacturing Class IIa and IIb medical devices—all ‘Made in France’.

This technological independence, certified under the GMED-issued international standard ISO 13485, enables us to support healthcare professionals and medical institutions worldwide.
Our medical devices are CE-marked and FDA-registered.
More than a manufacturer, CLERAD is an engaged and committed partner, providing after-sales service and maintenance activities backed up by dedicated technical assistance to ensure continuity of care.

About CLERAD

We are present
on 4 continents

Today, our expertise extends across four continents through a vast-reaching yet tightly-structured distribution network.

We have built up this international presence by selecting specialized partners who share our uncompromising standards on patient safety.

This global proximity enables us to deliver dependable technical and clinical support to clinicians anywhere in the world.

Technologies engineered
for healthcare professionals

Therapeutic de‑escalation

Our mission is to offer technologies that help reduce the aggressiveness of treatment while improving patient quality-of-life.

Operational efficiency

Designed and engineered for precision targeting and rapid execution, our devices facilitate optimized clinical procedures, improving clinical efficiency in daily practice.

Diagnostic and therapeutic support

From millimetric detection of micro-metastases to real-time control of healthy margins, we help directly improve medical procedures.

Safety and radiation protection

The use of low‑energy radiation and optimized shielding minimizes exposure for both patients and medical teams.

News

CLERAD announces the acquisition of Ariane Medical Systems Ltd.

15 May 2026
CLERAD announces the acquisition of Ariane Medical Systems Ltd., a UK-based company specializing in the development and commercialization of contact XRAY Brachytherapy solution.

Read more

2023 National Thesaurus – contact radiotherapy in the treatment of low and middle rectal cancers

13 May 2026
National recommendations for contact radiotherapy in specific indications for low & middle rectal cancers.

Read more

OPERA – 5 years results

12 May 2026
The OPERA trial has shown that a contact X-ray brachytherapy 50 kV (CXB) boost with neoadjuvant
chemoradiotherapy (NCRT) can increase organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of lowmid rectum.

Read more

See all articles

Contact Us

Contact Us

The content of this website is exclusively intended for healthcare professionals.